Intellectual Property

Q-Sera’s technology is based on research from the University of Queensland and is patent protected to 2035.

Family 1 Protection to Sept 2031

'Serum Preparation'
PCTAU2011/001221

This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.

All Jurisdictions granted: US, EU, Japan, China, Canada, Mexico, Russia, South Korea, South Africa, Australia, Israel, Brazil and India.

Family 2 Additional protection to Oct 2035

'Improved Clotting Composition'
PCTAU2015/000629

Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.

All Jurisdictions granted: US, EU, Japan, China, Canada, Australia and South Africa.